“Aderans Research Treats One-Hundredth Subject in Clinical Study (PRWeb)” plus 3 more |
- Aderans Research Treats One-Hundredth Subject in Clinical Study (PRWeb)
- Aderans Research Treats One-Hundredth Subject in Clinical Study (PRWeb via Yahoo! News)
- Groundbreaking Study Using Ultrasound For The Treatment Of Intracerebral And Intraventricular Hemorrhage Stroke Shows ... (Medical News Today)
- Beewolves protect their offspring with antibiotics; digger wasp larvae use bacteria against infections (Science Daily)
| Aderans Research Treats One-Hundredth Subject in Clinical Study (PRWeb) Posted: 28 Feb 2010 12:10 AM PST | Aderans Research Institute Inc. (ARI) recently achieved a significant milestone in its Phase 2 clinical study of cell-based hair regeneration, treating the trial's 100th subject. With clinical sites expected to double in the coming months, the study will likely add dozens of additional subjects to its enrollment. Atlanta, GA (PRWEB) February 28, 2010 -- Aderans Research Institute Inc. (ARI) recently achieved a significant milestone in its Phase 2 clinical study of cell-based hair regeneration, treating the trial's 100th subject. With clinical sites expected to double in the coming months, the study will likely add dozens of additional subjects to its enrollment. Phase 2 of the study has thus far been conducted in eight cities: Atlanta, Boston, Chicago, New York, Paramus, Raleigh, Houston, and Washington DC. The study will ultimately comprise at least 16 U.S. metropolitan areas, with numerous new cities expected to be added in the coming months. The second phase of the trial is testing a variety of treatment regimens designed to realize a unique autologous cell engineering solution to hair regeneration. During the treatment, a small section of hair-bearing tissue is removed, cells are extracted and cultivated in a controlled laboratory setting, and then reintroduced to the scalp, where they are expected to elicit new hair growth. "This is leading edge research in our industry," said Vern Liebmann, Vice President, Operations. "We've been able to conduct this study largely due to the generous financial backing of Aderans Co. LTD of Japan, and we're collectively very excited to see the results beginning later this year." Phase 1 of the clinical study was conducted exclusively in the UK. More than 30% of participants showed a viable response to ARI's cellular regeneration techniques. About Aderans Research Aderans Research is a pioneer in the research and development of safe, effective cell engineered products for hair regeneration. With offices in Atlanta and Philadelphia, Aderans Research Institute is a subsidiary of Aderans Company, Ltd, the world's largest wig manufacturer, and an affiliate of Bosley, a global leader in medical hair restoration. More information on ARI's study outcomes will be released as studies unfold. To see ARI's latest clinical updates, please visit http://aderansresearch.com/ari_clinicalupdates.html Additional information on ARI can be found at www.aderansresearch.com. Learn more about Aderans Co., Ltd. At http://www.aderans.co.jp/e/company/ ### Post Comment: Five Filters featured article: Chilcot Inquiry. Available tools: PDF Newspaper, Full Text RSS, Term Extraction. |
| Aderans Research Treats One-Hundredth Subject in Clinical Study (PRWeb via Yahoo! News) Posted: 27 Feb 2010 11:00 PM PST Aderans Research Institute Inc. (ARI) recently achieved a significant milestone in its Phase 2 clinical study of cell-based hair regeneration, treating the trial's 100th subject. With clinical sites expected to double in the coming months, the study will likely add dozens of additional subjects to its enrollment. Atlanta, GA (PRWEB) February 28, 2010 -- Aderans Research Institute Inc. (ARI) recently achieved a significant milestone in its Phase 2 clinical study of cell-based hair regeneration, treating the trial's 100th subject. With clinical sites expected to double in the coming months, the study will likely add dozens of additional subjects to its enrollment. "The breadth of this phase of our trial is tremendous," said Kurt Stenn, MD, Vice President and Chief Scientific Officer. "We have significantly more participants than our Phase 1 study. The improved quantity of our study group allows us to assess our cell-products and accelerate our efforts to truly understand the impact of cell regeneration on pattern hair loss." Phase 2 of the study has thus far been conducted in eight cities: Atlanta, Boston, Chicago, New York, Paramus, Raleigh, Houston, and Washington DC. The study will ultimately comprise at least 16 U.S. metropolitan areas, with numerous new cities expected to be added in the coming months. The second phase of the trial is testing a variety of treatment regimens designed to realize a unique autologous cell engineering solution to hair regeneration. During the treatment, a small section of hair-bearing tissue is removed, cells are extracted and cultivated in a controlled laboratory setting, and then reintroduced to the scalp, where they are expected to elicit new hair growth. "This is leading edge research in our industry," said Vern Liebmann, Vice President, Operations. "We've been able to conduct this study largely due to the generous financial backing of Aderans Co. LTD of Japan, and we're collectively very excited to see the results beginning later this year." Phase 1 of the clinical study was conducted exclusively in the UK. More than 30% of participants showed a viable response to ARI's cellular regeneration techniques. About Aderans Research Aderans Research is a pioneer in the research and development of safe, effective cell engineered products for hair regeneration. With offices in Atlanta and Philadelphia, Aderans Research Institute is a subsidiary of Aderans Company, Ltd, the world's largest wig manufacturer, and an affiliate of Bosley, a global leader in medical hair restoration. More information on ARI's study outcomes will be released as studies unfold. To see ARI's latest clinical updates, please visit http://aderansresearch.com/ari_clinicalupdates.html Additional information on ARI can be found at www.aderansresearch.com. Learn more about Aderans Co., Ltd. At http://www.aderans.co.jp/e/company/ ### Aderans Research Five Filters featured article: Chilcot Inquiry. Available tools: PDF Newspaper, Full Text RSS, Term Extraction. | |
| Posted: 27 Feb 2010 04:33 AM PST  Main Category: Stroke Also Included In: Neurology / Neuroscience; MRI / PET / Ultrasound; Conferences Article Date: 27 Feb 2010 - 1:00 PST David Newell, M.D., co-executive director of the Swedish Neuroscience Institute (SNI) in Seattle presented results of a groundbreaking study of 33 patients with spontaneous intracerebral hemorrhage who were screened for inclusion in a SNI clinical study known as 'SLEUTH' (Safety of Lysis with Ultrasound in the Treatment of Intracerebral and Intraventricular Hemorrhage). The presentation took place at the American Heart Association's International Stroke Conference in San Antonio, Texas. Co-authors of the study include Mohsin Shah, M.D., (SNI); Daniel F. Hanley, M.D., Johns Hopkins University Medical School (Baltimore, MD); Douglas Hansmann, Ph.D., and Robert Wilcox (Bothell, WA). Treatment was conducted in the operating room and included placement of a burr hole, as well as navigation of the ultrasound and drainage catheter into the hemorrhage using a GPS-like system (STEALTH) for optimal catheter placement. Ultrasound was then delivered to the hemorrhage, in addition to the thrombolytic (strong blood thinner) drug tissue plasminogen activator (rt-PA) for 24 hours. Intracerebral hemorrhage is a devastating form of stroke. Half of all patients die within one month of the event, and those who survive typically suffer dramatic loss of brain function and motor skills. Often, they are unable to resume normal activities such as caring for themselves, straining family members or requiring more extensive, expensive, ongoing, professional care further burdening the health-care system. "The more quickly a clot can be removed the better, and hours count. A minimally invasive treatment approach that combines catheter-delivered ultrasound in conjunction with a clot-busting drug was used," said Dr. Newell. "This new therapy has shown promising and encouraging results." "The most surprising thing we discovered was how rapidly the hemorrhage disappeared with ultrasound," said Dr. Newell. "And there were virtually no side effects, such as site infections or bleeding, during or after treatment." Dr. Newell emphasized that a multi-center trial for safety and efficacy with a redesigned catheter is warranted. "If this technique is proven to work on several hundred patients in a controlled study, it will provide huge benefits. Two million people worldwide experience intracerebral hemorrhage each year and there is no effective treatment available now. This has great potential to address the problem without cranial surgery." The Washington State Life Sciences Discovery Fund funded through money that Governor Christine Gregoire successfully helped appropriate for Washington state through the tobacco settlement provided a $170,000 grant, which allowed SNI to team with Bothell, Wash.-based EKOS Corporation to evaluate this innovative treatment. EKOS, which has been working with Dr. Newell since 2007, is now well positioned to pursue the commercial viability of this breakthrough therapy. Background on Intracerebral hemorrhage Intracerebral hemorrhage (ICH) occurs in more than 100,000 Americans each year and has no effective treatment. It is fatal in 30 percent to 50 percent of all occurrences and the majority of survivors have significant motor and cognitive disability. The severity of brain injury is related to the volume of blood clot and the exposure time. ICH is easily and rapidly identified. It occurs in younger patients, and it initially produces a smaller injury to the cerebral tissues, suggesting that improvement is possible with the right intervention that promotes effective blood-clot removal. ICH is frequently complicated by intraventricular hemorrhage (IVH). IVH increases mortality to as high as 80 percent. IVH obstructs cerebrospinal fluid (CSF) flow and leads to hydrocephalus. Re-establishing CSF flow is considered a neurosurgical emergency requiring ventricular catheter placement. These catheters control ICP, but do not enhance blood removal. Research demonstrating the value of blood removal suggests that rapid and complete removal is desirable, but rarely achieved rapidly with current technology. It has been recently demonstrated that ultrasound markedly increases the rate of blood-clot lysis (break down) produced by the thrombolytic substance recombinant tissue plasminogen activator (rt-PA). Current surgical care for ICH is open craniotomy, with a small, 4-percent benefit that remains controversial. Craniotomy can be associated with poor patient stability, substantial brain tissue injury, and frequent re-bleeding. In IVH a ventriculostomy (ventricular drain) is placed into the contra lateral ventricle to drain cerebrospinal fluid which can build up pressure. In contrast, data from human and animal models demonstrate that minimally invasive surgery (MIS) techniques and thrombolytics can substantially reduce blood-clot size and the area of brain tissue in direct contact with blood resulting in better patient stability, substantially decreased tissue injury, and minimal bleeding or infection. The long-term goal of this research is to change the way ICH and IVH are treated, reducing brain injury with catheter-based surgical and clinical management. This innovative approach combines local delivery of rt-PA with ultrasound enhancement to provide effective blood-clot removal. About Swedish Swedish is the largest, most comprehensive non-profit health provider in the Greater Seattle area. It is comprised of three hospital campuses First Hill, Cherry Hill and Ballard a freestanding emergency department and ambulatory care center in Issaquah, Swedish Visiting Nurse Services, and the Swedish Physician Division a network of more than 40 primary-care and specialty clinics located throughout the Puget Sound area. In the fall of 2009, Swedish broke ground on a new medical office building and hospital in the Issaquah Highlands, as well as a medical office building and ambulatory center in Ballard. In addition to general medical and surgical care, Swedish is known as a regional referral center, providing specialized treatment in areas such as cardiovascular care, cancer care, neuroscience, orthopedics, high-risk obstetrics, pediatric specialties, organ transplantation and clinical research. About Swedish Neuroscience Institute In 2004, Swedish expanded its neuroscience services by establishing the Swedish Neuroscience Institute. The team of leading neurosurgeons and other specialists are building a world-class institute dedicated solely to the treatment and advancement of neurological disorders for patients in the Pacific Northwest and around the world. Swedish/Cherry Hill has been designated as the hub for the Institute and has been upgraded with four state-of-the-art operating rooms featuring intra-operative MRI, CT scanning and neuro-interventional radiology capabilities; a renovated neuro intensive-care unit; and a CyberKnife® facility for radiosurgical treatment of tumors throughout the body. SNI specializes in the research for and treatment of stroke; cerebral aneurysms and arteriovenous malformations; movement disorders such as Parkinson's disease and tremors; brain tumors (including both malignant tumors and benign tumors such as meningiomas); neuro-endocrine disorders including pituitary tumors; epilepsy; child neurological disorders; neuro-ophthalmology; headaches; multiple sclerosis and many other neurological conditions and diseases. In each category, physicians from different specialties are brought together to provide a multi-disciplinary approach centered on providing top-notch patient care. Source: Swedish Neuroscience Institute
Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions. Contact Our News Editors For any corrections of factual information, or to contact the editors please use our feedback form. Five Filters featured article: Chilcot Inquiry. Available tools: PDF Newspaper, Full Text RSS, Term Extraction. | |
| Posted: 28 Feb 2010 06:29 PM PST ScienceDaily (Feb. 28, 2010) — Digger wasps of the genus Philanthus, so-called beewolves, house beneficial bacteria on their cocoons that guarantee protection against harmful microorganisms. Scientists of the Max Planck Institute for Chemical Ecology in Jena teamed up with researchers at the University of Regensburg and the Jena Leibniz Institute for Natural Product Research -- Hans-Knoell-Institute -- and discovered that bacteria of the genus Streptomyces produce a cocktail of nine different antibiotics and thereby fend off invading pathogens. Using imaging techniques based on mass spectrometry, the antibiotics could be displayed in vivo on the cocoon's exterior surface. Moreover, it was shown that the use of different kinds of antibiotics provides an effective protection against infection with a multitude of different pathogenic microorganisms. Thus, for millions of years beewolves have been taking advantage of a principle that is known as combination prophylaxis in human medicine. The research appears in Nature Chemical Biology, Advance Online Publication, February 28, 2010. Many insects spend a part of their life underground and are exposed to the risk of fungal or bacterial infections. This is also the case for many digger wasp species that construct underground nests. Unlike bees that use pollen and nectar as food to nurture their larvae, digger wasps hunt insects to feed their offspring. Because of the warm and humid conditions as well as the large amounts of organic material in their subterranean nest, both their food supply and their larvae are endangered by pathogens -- mold and bacterial infection are a major threat and can cause larval death in many cases. Symbiosis with bacteria increases survival rate of beewolf larvae Beewolves, i.e. digger wasps that hunt for bees to feed their larvae, have evolved an elegant solution to the problem of fungal and bacterial infection. Martin Kaltenpoth and colleagues from the University of Wurzburg had already shown several years ago that beewolves form a symbiotic relationship with bacteria of the genus Streptomyces. Female beewolves cultivate these bacteria in specialized antennal gland reservoirs and apply them to the ceiling of the brood cells. Beewolf larvae later take up the bacteria and transfer the symbionts actively to their cocoons, thereby increasing their survival probability. However, it has been unclear so far how the protection is achieved. Scientists of the groups of Aleš Svatoš and Martin Kaltenpoth at the Max Planck Institute in cooperation with their colleagues at the University of Regensburg and the Hans-Knoell-Institute in Jena now discovered that the symbionts produce nine different antibiotic substances. For the first time the biologists were able to identify these substances directly in the natural environment, i.e. on the beewolf cocoon. Other studies on protective symbioses could detect antibiotic substances only after isolation and cultivation of the symbionts in artificial culture media. By means of a novel technique of imaging mass spectrometry (LDI imaging), the Jena scientists could demonstrate that the antibiotics are primarily present on the exterior of the cocoon, reducing the risk of potentially harmful side-effects on the larvae. "Combination Medication" broadens the spectrum of efficacy In biotests with different pathogenic fungi and bacteria the scientists observed that beewolves utilize the principle of combination medication: "A combined treatment with streptochlorin and eight different piericidines we were able to isolate from the cocoon helps to fend off a very broad spectrum of microorganisms; this cannot be achieved with a single substance. This means that millions of years ago, beewolves and their symbionts have already evolved a strategy that is known from human medicine as combination prophylaxis" explains Johannes Kroiss, first author of the study. With their work the researchers break new ground: "Astonishingly, little is known about the ecological importance of antibiotics in their natural environment. Supported by mass spectrometric imaging we are now able to better understand the natural role of antibiotic substances in the environment," says Aleš Svatoš, leader of the mass spectrometry research group. The imaging techniques can help to provide important insights, especially into the exploration of symbiotic interactions. "We suppose that protective symbioses like the ones between beewolves and Streptomyces bacteria are much more common in the animal kingdom than previously assumed," says Martin Kaltenpoth, who heads a Max Planck Research Group on Insect-Bacteria Symbiosis since January. "An analysis of the substances involved not only contributes to the understanding of the evolution of such symbioses but could also lead to the discovery of interesting new drug candidates for human medicine." [JK/MK/AO] Story Source: Adapted from materials provided by Max Planck Institute for Chemical Ecology, via EurekAlert!, a service of AAAS. Journal Reference:
Note: If no author is given, the source is cited instead. Five Filters featured article: Chilcot Inquiry. Available tools: PDF Newspaper, Full Text RSS, Term Extraction. |
"The breadth of this phase of our trial is tremendous," said Kurt Stenn, MD, Vice President and Chief Scientific Officer. "We have significantly more participants than our Phase 1 study. The improved quantity of our study group allows us to assess our cell-products and accelerate our efforts to truly understand the impact of cell regeneration on 
email to a friend
printer friendly
view / write opinions| You are subscribed to email updates from Yahoo! News Search Results for Study Techniques To stop receiving these emails, you may unsubscribe now. | Email delivery powered by Google |
| Google Inc., 20 West Kinzie, Chicago IL USA 60610 | |
No comments:
Post a Comment